Cancer Cell provides a high-profile forum to promote major advances in cancer research and oncology. The primary criterion for considering manuscripts is whether the studies provide major advances into answering important questions relevant to naturally occurring cancers. Cancer Cell particularly welcomes translational research. Cancer Cell is also interested in publishing clinical investigations, in particular those that lead to establishing new paradigms in the treatment, diagnosis, or prevention of cancers; those that provide important insights into cancer biology beyond what has been revealed by preclinical studies; and those that are mechanism-based proof-of-principle clinical studies.
癌细胞提供了一个高姿态的论坛，以促进癌症研究和肿瘤学的重大进展。考虑稿件的主要标准是研究是否在回答与自然发生的癌症相关的重要问题方面提供了重大进展。Cancer Cell特别欢迎转化研究。《癌细胞》杂志也有兴趣发表临床研究，特别是那些导致建立癌症治疗、诊断或预防新模式的研究;提供超出临床前研究所揭示的对癌症生物学的重要见解的那些;和基于机理的原理验证临床研究。
Targeting Ferroptosis to Iron Out Cancer.
来源期刊：Cancer cellDOI：10.1016/j.ccell.2019.04.002
Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies.
来源期刊：Cancer cellDOI：10.1016/j.ccell.2019.02.001
Gain Fat-Lose Metastasis: Converting Invasive Breast Cancer Cells into Adipocytes Inhibits Cancer Metastasis.
来源期刊：Cancer cellDOI：10.1016/j.ccell.2018.12.002
Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells.
来源期刊：Cancer cellDOI：10.1016/j.ccell.2019.01.002
Histone H3.3 K27M Accelerates Spontaneous Brainstem Glioma and Drives Restricted Changes in Bivalent Gene Expression.
来源期刊：Cancer cellDOI：10.1016/j.ccell.2018.11.015
Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia.
来源期刊：Cancer cellDOI：10.1016/j.ccell.2019.01.010
A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK.
来源期刊：Cancer cellDOI：10.1016/j.ccell.2019.01.009
Glycosylation in the Era of Cancer-Targeted Therapy: Where Are We Heading?
来源期刊：Cancer cellDOI：10.1016/j.ccell.2019.06.006
Epithelial NOTCH Signaling Rewires the Tumor Microenvironment of Colorectal Cancer to Drive Poor-Prognosis Subtypes and Metastasis
来源期刊：Cancer CellDOI：10.1016/j.ccell.2019.08.003
Proteogenomic Characterization of Human Early-Onset Gastric Cancer.
来源期刊：Cancer cellDOI：10.1016/j.ccell.2018.12.003
Combination of Hypoglycemia and Metformin Impairs Tumor Metabolic Plasticity and Growth by Modulating the PP2A-GSK3β-MCL-1 Axis.
来源期刊：Cancer cellDOI：10.1016/j.ccell.2019.03.007
Pangenomic Classification of Pituitary Neuroendocrine Tumors.
来源期刊：Cancer cellDOI：10.1016/j.ccell.2019.11.002
Mubritinib Targets the Electron Transport Chain Complex I and Reveals the Landscape of OXPHOS Dependency in Acute Myeloid Leukemia.
来源期刊：Cancer cellDOI：10.1016/j.ccell.2019.06.003
Toward the Early Detection of Cancer by Decoding the Epigenetic and Environmental Fingerprints of Cell-Free DNA.
来源期刊：Cancer cellDOI：10.1016/j.ccell.2019.09.003
Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy.
来源期刊：Cancer cellDOI：10.1016/j.ccell.2019.10.001
The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression.
来源期刊：Cancer cellDOI：10.1016/j.ccell.2019.06.009
Clonally Expanded T Cells Reveal Immunogenicity of Rhabdoid Tumors.
来源期刊：Cancer cellDOI：10.1016/j.ccell.2019.10.008
HOTTIP lncRNA Promotes Hematopoietic Stem Cell Self-Renewal Leading to AML-like Disease in Mice
来源期刊：Cancer cellDOI：10.1016/j.ccell.2019.10.011
Targeting TMEM176B Enhances Antitumor Immunity and Augments the Efficacy of Immune Checkpoint Blockers by Unleashing Inflammasome Activation
来源期刊：Cancer CellDOI：10.1016/j.ccell.2019.04.003
Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF.
来源期刊：Cancer cellDOI：10.1016/j.ccell.2019.03.002
p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors.
来源期刊：Cancer cellDOI：10.1016/j.ccell.2019.01.006
Pan-cancer Convergence to a Small-Cell Neuroendocrine Phenotype that Shares Susceptibilities with Hematological Malignancies.
来源期刊：Cancer cellDOI：10.1016/j.ccell.2019.06.005
p62/SQSTM1 Fuels Melanoma Progression by Opposing mRNA Decay of a Selective Set of Pro-metastatic Factors.
来源期刊：Cancer cellDOI：10.1016/j.ccell.2018.11.008
The ERBB-STAT3 Axis Drives Tasmanian Devil Facial Tumor Disease
来源期刊：Cancer CellDOI：10.1016/j.ccell.2018.11.018
Paradigms for Precision Medicine in Epichaperome Cancer Therapy.
来源期刊：Cancer cellDOI：10.1016/j.ccell.2019.09.007
LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL.
来源期刊：Cancer cellDOI：10.1016/j.ccell.2019.07.007
Protein Kinase Cι and Wnt/β-Catenin Signaling: Alternative Pathways to Kras/Trp53-Driven Lung Adenocarcinoma.
来源期刊：Cancer cellDOI：10.1016/j.ccell.2019.07.002
Passenger Hotspot Mutations in Cancer.
来源期刊：Cancer cellDOI：10.1016/j.ccell.2019.08.002
Hijacking EMT: Better Fat Than Dead.
来源期刊：Cancer cellDOI：10.1016/j.ccell.2018.12.007
Oncogenic KRAS Drives Immune Suppression in Colorectal Cancer.
来源期刊：Cancer cellDOI：10.1016/j.ccell.2019.03.008
γ-Catenin-Dependent Signals Maintain BCR-ABL1+ B Cell Acute Lymphoblastic Leukemia.
来源期刊：Cancer cellDOI：10.1016/j.ccell.2019.03.005
Colon Cancer: Epithelial Notch Signaling Recruits Neutrophils to Drive Metastasis.
来源期刊：Cancer cellDOI：10.1016/j.ccell.2019.08.010
Recruit or Reboot? How Does Anti-PD-1 Therapy Change Tumor-Infiltrating Lymphocytes?
来源期刊：Cancer cellDOI：10.1016/j.ccell.2019.08.009
The Stromal and Immune Landscape of Colorectal Cancer Progression during Anti-EGFR Therapy.
来源期刊：Cancer cellDOI：10.1016/j.ccell.2019.06.001
Acquired Resistance Is Oncogene and Drug Agnostic.
来源期刊：Cancer cellDOI：10.1016/j.ccell.2019.09.011
Venetoclax in Lymphoid Malignancies: New Insights, More to Learn.
来源期刊：Cancer cellDOI：10.1016/j.ccell.2019.09.008
Doomed from the TERT? A Two-Stage Model of Tumorigenesis in IDH-Wild-Type Glioblastoma.
来源期刊：Cancer cellDOI：10.1016/j.ccell.2019.03.009
The Direct Molecular Target for Imipridone ONC201 Is Finally Established.
来源期刊：Cancer cellDOI：10.1016/j.ccell.2019.04.010
M-TAP Dance: Targeting PRMT1 and PRMT5 Family Members to Push Cancer Cells Over the Edge.
来源期刊：Cancer cellDOI：10.1016/j.ccell.2019.06.004
Fatty Acids Corrupt Neutrophils in Cancer.
来源期刊：Cancer cellDOI：10.1016/j.ccell.2019.05.007
The Origin of CIMP, At Last.
来源期刊：Cancer cellDOI：10.1016/j.ccell.2019.01.015
A Positive Step toward Understanding Double-Negative Metastatic Prostate Cancer.
来源期刊：Cancer cellDOI：10.1016/j.ccell.2019.07.006
Overcoming Treatment Toxicity through Sequential Therapy.
来源期刊：Cancer cellDOI：10.1016/j.ccell.2019.05.006
Companion Diagnostics to Identify Biomarkers of Response to Anticancer Drugs Targeting the Proteome.
来源期刊：Cancer cellDOI：10.1016/j.ccell.2019.10.003
Teaching an Old Drug New Tricks.
来源期刊：Cancer cellDOI：10.1016/j.ccell.2019.04.008
Thrown for a Loop: Awakening BORIS to Evade ALK Inhibition Therapy.
来源期刊：Cancer cellDOI：10.1016/j.ccell.2019.09.009
LMO2 as a Biomarker for Hypersensitivity to Genotoxic Therapy.
来源期刊：Cancer cellDOI：10.1016/j.ccell.2019.08.011
PRC2 Plays Red Light, Green Light with MHC-I and CD8+ T Cells.
来源期刊：Cancer cellDOI：10.1016/j.ccell.2019.09.010
Tails of a Super Histone.
来源期刊：Cancer cellDOI：10.1016/j.ccell.2018.12.005
Stressing Out about Cancer Immunotherapy.
来源期刊：Cancer cellDOI：10.1016/j.ccell.2019.10.013
